12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations MENLO PARK, ...
Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no ...
MENLO PARK, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...
Please provide your email address to receive an email when new articles are posted on . The Omni procedure helped reduce IOP across all severities of glaucoma. The procedure produced a low secondary ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A study looked at real-world outcomes with Omni, Hydrus, ...
A Meta-Analysis of 22 Studies, and Data from the IRIS ® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication ...
Sight Sciences Inc. (NASDAQ:SGHT) on Tuesday announced that UnitedHealthcare has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and ...
MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing ...
Due to a strong family history of JOAG, a 9-month child was found to be positive for MYOC mutation. Ocular hypertension was first detected at age 11 years and topical medical treatment commenced. At ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results